Results 121 to 130 of about 19,369 (169)

From MAiD Referral to Targeted Therapy Success: A Case of <i>BRAF</i>-Mutated Anaplastic Thyroid Cancer. [PDF]

Reports (MDPI)
Stubbert B, Stewart P, Winquist E, Cecchini M, Browne C.   +4 more
europepmc   +1 more source

First Report of Trametinib-Nintedanib Combination in KRAS G12D-Mutated Pancreatic Cancer: Efficacy and Fatal Hemorrhagic Complication: A Case Report. [PDF]

Clin Case Rep
Zhao Y, Yuan L, Wang S, Wu C.
europepmc   +1 more source

WNT signalling promotes NF-κB activation and drug resistance in KRAS-mutant colorectal cancer. [PDF]

EMBO Rep
Cong B, Stamou E, Pennel K, Thakur T, Mckenzie M, Matly A, Gilroy K, Shah H, Gopinath S, Edwards J, Cagan R.   +10 more
europepmc   +1 more source

ULK1 promotes metastatic progression in experimental models of epithelial ovarian cancer. [PDF]

Oncogene
Webb JD, Buensuceso A, Tomas EJ, Borrelli MJ, Viola L, Hovey O, Ramos Valdes Y, Singha B, Li SS, Shepherd TG.   +9 more
europepmc   +1 more source

A case report of neoadjuvant targeted therapy in stage IIIA non-small cell lung cancer with <i>BRAF V600E</i> mutation. [PDF]

Front Med (Lausanne)
Peng W, Qu S, Cai L, Yang R, Dong M, Li X, Ran F, Luo C.   +7 more
europepmc   +1 more source

Melanoma: Pathogenesis and Targeted Therapy. [PDF]

MedComm (2020)
Fu Y, Liu J, Mo Z, Wang B, Deng Y, Jiang Y.   +5 more
europepmc   +1 more source

A PP2A molecular glue overcomes RAS/MAPK inhibitor resistance in KRAS-mutant non-small cell lung cancer. [PDF]

J Clin Invest
Raines B, Tseng-Rogenski S, Dowdican AC, Peris I, Hinderman M, Zawacki KP, Barrie K, Hodges Onishi G, Dymond AM, Luther TK, Musser S, Karaj Majchrowski B, Brenner JC, Ahmed A, Taylor DJ, O'Connor CM, Narla G.   +16 more
europepmc   +1 more source

An Adult Case of Chest Wall Langerhans Cell Histiocytosis Mimicking Malignancy and Responding to Targeted Therapy. [PDF]

Cureus
Alchaer MW, Capelli T, Abbruzzese TA, Wright A.   +3 more
europepmc   +1 more source

Pathway-Specific Therapeutic Modulation of Melanoma: Small-Molecule Inhibition of BRAF-MEK and KIT Signaling in Contemporary Precision Oncology with a Special Focus on Vemurafenib, Trametinib, and Imatinib. [PDF]

J Clin Med
Kawczak P, Bączek T.
europepmc   +1 more source